Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series
Abstract The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain p...
Gespeichert in:
| Veröffentlicht in: | Cancer treatment communications 2016, Vol.7, p.43-46 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | |
| container_start_page | 43 |
| container_title | Cancer treatment communications |
| container_volume | 7 |
| creator | Keith, Kevin C Lee, Yueh Ewend, Matthew G Zagar, Timothy M Anders, Carey K |
| description | Abstract The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients. Size constraints are believed to prevent larger monoclonal antibodies, such as pertuzumab and trastuzumab, from crossing the blood brain barrier (BBB). However, emerging evidence reveals that the BBB is perturbed in the setting of metastases, allowing for improved penetrance of these larger targeted agents. The disrupted BBB may allow for passage of ado-trastuzumab emtansine (TDM1), though little clinical information about its activity in BCBM patients is currently known. |
| doi_str_mv | 10.1016/j.ctrc.2016.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4840897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2213089616300160</els_id><sourcerecordid>1826670983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4255-d284dc1ed48fde83b69fb1fb013797f7872b2a7e588d511eaac29aca2295accb3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQtRCIVqV_gAPKsRwSbOfLQajSqhSKVITUlvPIcSbFSz62nmSl5dcz0Zaq9NCTx5733oznjRBvlUyUVMWHdeKm4BLNcSLTRMr8hTjUWqWxNFXx8lF8II6J1lJKlepcG_laHOhSqcxU-aG4XbnJb_20i8Y2moKlaf4z97aOsZ_sQH7A6OTm83f1PvJDdHF-pePNSJ4pGNUBGR45OzgMfLOM6HHiN0tIH6MVpwgjwuCR3ohXre0Ij-_PI_Hzy_nN2UV8-ePrt7PVZewynedxo03WOIVNZtoGTVoXVVurtubey6psS1PqWtsSc2OaXCm01unKOqt1lVvn6vRInO51N3PdY-Nw4E91sAm-t2EHo_Xwf2bwv-B23EJmMh5WyQIn9wJhvJuRJug9Oew6O-A4Eyiji6KUlUkZqvdQF0aigO1DGSVhMQnWsJgEi0kgU2CTmPTucYMPlH-WMODTHoA8pq3HAOQ88owbH9BN0Iz-ef3TJ3TX-cE72_3GHdJ6nMPABoAC0iDhelmTZUtUkfKGFDL9C26OuTY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826670983</pqid></control><display><type>article</type><title>Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series</title><source>Alma/SFX Local Collection</source><creator>Keith, Kevin C ; Lee, Yueh ; Ewend, Matthew G ; Zagar, Timothy M ; Anders, Carey K</creator><creatorcontrib>Keith, Kevin C ; Lee, Yueh ; Ewend, Matthew G ; Zagar, Timothy M ; Anders, Carey K</creatorcontrib><description>Abstract The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients. Size constraints are believed to prevent larger monoclonal antibodies, such as pertuzumab and trastuzumab, from crossing the blood brain barrier (BBB). However, emerging evidence reveals that the BBB is perturbed in the setting of metastases, allowing for improved penetrance of these larger targeted agents. The disrupted BBB may allow for passage of ado-trastuzumab emtansine (TDM1), though little clinical information about its activity in BCBM patients is currently known.</description><identifier>ISSN: 2213-0896</identifier><identifier>EISSN: 2213-0896</identifier><identifier>DOI: 10.1016/j.ctrc.2016.03.005</identifier><identifier>PMID: 27114895</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adotrastuzumab ; Brain metastasis ; Breast cancer ; Emtansine ; Hematology, Oncology and Palliative Medicine ; Kadcyla ; T-DM1</subject><ispartof>Cancer treatment communications, 2016, Vol.7, p.43-46</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4255-d284dc1ed48fde83b69fb1fb013797f7872b2a7e588d511eaac29aca2295accb3</citedby><cites>FETCH-LOGICAL-c4255-d284dc1ed48fde83b69fb1fb013797f7872b2a7e588d511eaac29aca2295accb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27114895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keith, Kevin C</creatorcontrib><creatorcontrib>Lee, Yueh</creatorcontrib><creatorcontrib>Ewend, Matthew G</creatorcontrib><creatorcontrib>Zagar, Timothy M</creatorcontrib><creatorcontrib>Anders, Carey K</creatorcontrib><title>Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series</title><title>Cancer treatment communications</title><addtitle>Cancer Treat Commun</addtitle><description>Abstract The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients. Size constraints are believed to prevent larger monoclonal antibodies, such as pertuzumab and trastuzumab, from crossing the blood brain barrier (BBB). However, emerging evidence reveals that the BBB is perturbed in the setting of metastases, allowing for improved penetrance of these larger targeted agents. The disrupted BBB may allow for passage of ado-trastuzumab emtansine (TDM1), though little clinical information about its activity in BCBM patients is currently known.</description><subject>Adotrastuzumab</subject><subject>Brain metastasis</subject><subject>Breast cancer</subject><subject>Emtansine</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Kadcyla</subject><subject>T-DM1</subject><issn>2213-0896</issn><issn>2213-0896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9Uk1v1DAQtRCIVqV_gAPKsRwSbOfLQajSqhSKVITUlvPIcSbFSz62nmSl5dcz0Zaq9NCTx5733oznjRBvlUyUVMWHdeKm4BLNcSLTRMr8hTjUWqWxNFXx8lF8II6J1lJKlepcG_laHOhSqcxU-aG4XbnJb_20i8Y2moKlaf4z97aOsZ_sQH7A6OTm83f1PvJDdHF-pePNSJ4pGNUBGR45OzgMfLOM6HHiN0tIH6MVpwgjwuCR3ohXre0Ij-_PI_Hzy_nN2UV8-ePrt7PVZewynedxo03WOIVNZtoGTVoXVVurtubey6psS1PqWtsSc2OaXCm01unKOqt1lVvn6vRInO51N3PdY-Nw4E91sAm-t2EHo_Xwf2bwv-B23EJmMh5WyQIn9wJhvJuRJug9Oew6O-A4Eyiji6KUlUkZqvdQF0aigO1DGSVhMQnWsJgEi0kgU2CTmPTucYMPlH-WMODTHoA8pq3HAOQ88owbH9BN0Iz-ef3TJ3TX-cE72_3GHdJ6nMPABoAC0iDhelmTZUtUkfKGFDL9C26OuTY</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Keith, Kevin C</creator><creator>Lee, Yueh</creator><creator>Ewend, Matthew G</creator><creator>Zagar, Timothy M</creator><creator>Anders, Carey K</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2016</creationdate><title>Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series</title><author>Keith, Kevin C ; Lee, Yueh ; Ewend, Matthew G ; Zagar, Timothy M ; Anders, Carey K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4255-d284dc1ed48fde83b69fb1fb013797f7872b2a7e588d511eaac29aca2295accb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adotrastuzumab</topic><topic>Brain metastasis</topic><topic>Breast cancer</topic><topic>Emtansine</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Kadcyla</topic><topic>T-DM1</topic><toplevel>online_resources</toplevel><creatorcontrib>Keith, Kevin C</creatorcontrib><creatorcontrib>Lee, Yueh</creatorcontrib><creatorcontrib>Ewend, Matthew G</creatorcontrib><creatorcontrib>Zagar, Timothy M</creatorcontrib><creatorcontrib>Anders, Carey K</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer treatment communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keith, Kevin C</au><au>Lee, Yueh</au><au>Ewend, Matthew G</au><au>Zagar, Timothy M</au><au>Anders, Carey K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series</atitle><jtitle>Cancer treatment communications</jtitle><addtitle>Cancer Treat Commun</addtitle><date>2016</date><risdate>2016</risdate><volume>7</volume><spage>43</spage><epage>46</epage><pages>43-46</pages><issn>2213-0896</issn><eissn>2213-0896</eissn><abstract>Abstract The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients. Size constraints are believed to prevent larger monoclonal antibodies, such as pertuzumab and trastuzumab, from crossing the blood brain barrier (BBB). However, emerging evidence reveals that the BBB is perturbed in the setting of metastases, allowing for improved penetrance of these larger targeted agents. The disrupted BBB may allow for passage of ado-trastuzumab emtansine (TDM1), though little clinical information about its activity in BCBM patients is currently known.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27114895</pmid><doi>10.1016/j.ctrc.2016.03.005</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-0896 |
| ispartof | Cancer treatment communications, 2016, Vol.7, p.43-46 |
| issn | 2213-0896 2213-0896 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4840897 |
| source | Alma/SFX Local Collection |
| subjects | Adotrastuzumab Brain metastasis Breast cancer Emtansine Hematology, Oncology and Palliative Medicine Kadcyla T-DM1 |
| title | Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A03%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20trastuzumab-emtansine%20(TDM1)%20in%20HER2-positive%20breast%20cancer%20brain%20metastases:%20A%20case%20series&rft.jtitle=Cancer%20treatment%20communications&rft.au=Keith,%20Kevin%20C&rft.date=2016&rft.volume=7&rft.spage=43&rft.epage=46&rft.pages=43-46&rft.issn=2213-0896&rft.eissn=2213-0896&rft_id=info:doi/10.1016/j.ctrc.2016.03.005&rft_dat=%3Cproquest_pubme%3E1826670983%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826670983&rft_id=info:pmid/27114895&rft_els_id=1_s2_0_S2213089616300160&rfr_iscdi=true |